Skip to main content

Table 2 Toxicity maximum grade per patient – attributable to treatment

From: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

Toxicity type

Description

Grade

  
  

1

2

3

BL101

Anemia

0

0

2

BL999

Blood and lymphatic system disorders - Other

1

0

0

CN108

Fatigue

3

0

0

CN109

Fever

2

0

0

CN121

Non-cardiac chest pain

1

0

0

GI121

Constipation

1

0

0

GI123

Diarrhea

1

0

0

GI124

Dry mouth

2

0

0

GI179

Nausea

2

1

0

GI210

Stomach pain

1

0

0

GI216

Vomiting

3

0

0

GI999

Gastrointestinal disorders - Other

1

0

0

IN171

Urinary tract infection

1

0

0

IV127

Lymphocyte count decreased

0

0

1

IV131

Platelet count decreased

0

1

1

ME999

Metabolism and nutrition disorders - Other

2

0

0

MU112

Generalized muscle weakness

1

0

0

MU999

Musculoskeletal and connective tissue disorder - Other

1

0

0

NE118

Dysgeusia

1

0

0

NE126

Headache

1

0

0

PU113

Cough

1

0

0

PU999

Respiratory, thoracic and mediastinal disorders - Other

1

0

0

VA102

Flushing

1

0

0

VA104

Hot flashes

1

0

0

TOTAL

 

29

2

4

Worst grade per patient across all types

 
 

Count

Percentage

Mild - grade 1 as worst degree

5

45.45%

Moderate - grade 2 as worst degree

1

9.09%

Severe - grade 3 as worst degree

4

36.36%

Life threatening

1

9.09%